The Manufacturers Life Insurance Company Has $196,000 Stock Holdings in Urogen Pharma $URGN

The Manufacturers Life Insurance Company decreased its position in Urogen Pharma (NASDAQ:URGN) by 80.4% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 10,909 shares of the company’s stock after selling 44,777 shares during the period. The Manufacturers Life Insurance Company’s holdings in Urogen Pharma were worth $196,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after acquiring an additional 486 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares in the last quarter. Finally, ProShare Advisors LLC bought a new position in Urogen Pharma in the fourth quarter valued at $206,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider directly owned 119,763 shares in the company, valued at $4,790,520. This trade represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 25,222 shares of company stock valued at $892,661. 4.80% of the stock is owned by corporate insiders.

Urogen Pharma Price Performance

URGN stock opened at $49.14 on Tuesday. Urogen Pharma has a one year low of $15.86 and a one year high of $49.67. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -24.82 and a beta of 1.57. The company has a fifty day moving average price of $38.96 and a two-hundred day moving average price of $28.36.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. Research analysts anticipate that Urogen Pharma will post -0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on URGN. LADENBURG THALM/SH SH assumed coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 price target on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $44.00 price objective on shares of Urogen Pharma in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Friday, July 17th. TD Cowen upped their target price on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $50.38.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.